Diabetes drugs under scrutiny for possible risks

Published



A look at the diabetes drugs under investigation by the U.S. Food and Drug Administration over possible risks of pancreas inflammation and cellular changes in the pancreas that occur before cancer.

DRUG CLASS: GLP-1 mimickers, taken by nearly 1 million Americans.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.